GSK, Arecor form vaccine stabilization pact

GlaxoSmithKline and Arecor have entered a collaboration to advance GSK's vaccines using Arecor's stabilization technology. Exact financial detail weren't disclosed, but the company's release stated Arecor would receive milestone payments and royalties.

"Arecor is pleased to work closely with one of the global leaders in vaccine products and technology," said Tom Saylor, CEO of Arecor, in a release. "The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilisation to specific projects with GSK."

Cambridge, U.K.-based Arecor has patented stabilization tools that combat biologics' degradation. GSK and Arecor believe this will extend the usability of GSK vaccines.

- read the Arecor release
- here's more from inPharm

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.